Reckitt Benckiser narrows sales target as Q3 sales grow
Sharecast
Published Oct 26, 2022 08:36
Reckitt Benckiser narrows sales target as Q3 sales grow
Like-for-like revenues grew 7.4%, with Reckitt hailing continued broad-based growth and momentum.
LFL sales in the hygiene segment dipped 1.2%. However, excluding the Lysol disinfectant spray, sales were up 3.3%, led by Finish, Harpic, and Vanish. Reckitt said the volume declines in Lysol were expected due to tough comparatives.
In the health business, LFL sales were up 10.7%, led by over-the-counter brands such as Mucinex, Nurofen and Strepsils, and the company’s Intimate Wellness portfolio of Durex and KY.
LFL growth in nutrition was 24.7%. This was driven by mid-single digit growth in developing markets and over 40% growth in the US, with strong execution amidst temporary infant formula shortages. Growth includes an estimated 20.3% benefit from temporary competitor supply issues, the company said.
Reckitt narrowed the range of its LFL net revenue growth target for 2022 to between 6% and 8% from between 5% and 8% previously. The group said it is already delivering sustainable mid-single digit net revenue growth, and remains "firmly on track" to deliver its medium-term goal of mid-20s adjusted operating margins by the mid-2020s.
Chief executive Nicando Durante said: "Reckitt delivered another quarter of broad-based growth amidst challenging market conditions, as we continue to innovate and improve on our in-market execution.
"We have an excellent portfolio of trusted, market-leading brands in high margin, high-growth categories and a strong culture of ownership and delivery. My priority is firmly focussed on continuing to execute on our strategic path, to deliver sustainable mid-single digit growth, and mid-20s adjusted operating margins by the mid-2020s."
Read more on Sharecast.com
Get The App
Written By: Sharecast
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.